Profitability Metrics

Gross Margin
116.73%
Operating Margin
112.08%
Net Margin
155.75%

Efficiency Metrics

Revenue per Expense Ratio
-1.46
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
112.08%
Income Tax Rate
273,100,000.0%
EPS
-3.2600000000

Balance Sheet Analysis

Current Ratio
70.10
Cash Ratio
149.35
Working Capital
$24.60M
Debt to Equity
0.22
Debt to Assets
17.93%
Equity Ratio
80.58%

Cash Flow Analysis

Operating Cash Flow Ratio
20.05%
Free Cash Flow Ratio
20.06%
CapEx to Revenue
0.00%
Dividends Paid
$18.03M
Stock Buybacks
No buybacks
Total Shareholder Returns
$18.03M
Cash Position Change
1,885.0%

Key Takeaways (2023 FY)

  • Revenue declined by 189.08186073052%, indicating potential market challenges

Detailed Growth Metrics

Core Performance

Revenue
-189.08%
Net Income
-339.75%
EPS
-348.85%
Operating Income
-229.13%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
0.33%
Operating Cash Flow
-134.64%
Free Cash Flow
-134.64%

Balance Sheet Health

Assets
-10.19%
Debt
14.95%
Book Value per Share
-13.42%
Inventory
100.00%

Shareholder Returns

Dividends per Share
-22.56%
Shares Outstanding
0.44%

Long Term Trends

3Y Revenue/Share
19.54%
5Y Revenue/Share
-249.72%
3Y Dividend/Share
-58.73%
5Y Dividend/Share
-76.40%